Is Celldex Therapeutics, Inc. overvalued or undervalued?

As of 9 November 2022, the valuation grade for Celldex Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company is currently assessed as overvalued, given its troubling financial ratios, including a Price to Book Value of 2.02 and an EV to EBITDA of -3.51. Additionally, the Return on Capital Employed (ROCE) stands at a staggering -584.07%, which raises serious concerns about its operational efficiency and profitability.
When compared to its peers, Celldex's performance is notably poor. For instance, Hims & Hers Health, Inc. has a P/E ratio of 77.97, while RadNet, Inc. shows a P/E of 132.34, both of which highlight the stark contrast in valuation metrics. Furthermore, Celldex's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -19.31% compared to the index's 2.44%, reinforcing the notion that the stock is currently overvalued in the market.